ArticleDiabetology & metabolic syndrome2022

The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial.

Sepehr Gohari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.